151 results on '"Del Medico P."'
Search Results
2. A rare presentation of heart failure with preserved ejection fraction
- Author
-
Donadoni, Mattia, Petullà, Marina, Del Medico, Marta, Barosi, Alberto, and Wu, Maddalena Alessandra
- Published
- 2023
- Full Text
- View/download PDF
3. Resonant plasmonic micro-racetrack modulators with high bandwidth and high temperature tolerance
- Author
-
Eppenberger, Marco, Messner, Andreas, Bitachon, Bertold Ian, Heni, Wolfgang, Blatter, Tobias, Habegger, Patrick, Destraz, Marcel, De Leo, Eva, Meier, Norbert, Del Medico, Nino, Hoessbacher, Claudia, Baeuerle, Benedikt, and Leuthold, Juerg
- Published
- 2023
- Full Text
- View/download PDF
4. Two-years chest-CT follow-up after severe COVID-19 pneumonia
- Author
-
Flor, Nicola, Leidi, Federica, Casella, Francesco, Mariani, Leonardo, Piazza, Mattia, Del Medico, Marta, and Cogliati, Chiara Beatrice
- Published
- 2023
- Full Text
- View/download PDF
5. Apremilast retention rate in clinical practice: observations from an Italian multi-center study
- Author
-
Ariani, Alarico, Parisi, Simone, Del Medico, Patrizia, Farina, Antonella, Visalli, Elisa, Molica Colella, Aldo Biagio, Lumetti, Federica, Caccavale, Rosalba, Scolieri, Palma, Andracco, Romina, Girelli, Francesco, Bravi, Elena, Colina, Matteo, Volpe, Alessandro, Ianniello, Aurora, Franchina, Veronica, Platè, Ilaria, Di Donato, Eleonora, Amato, Giorgio, Salvarani, Carlo, Lucchini, Gianluca, De Lucia, Francesco, Molica Colella, Francesco, Santilli, Daniele, Ferrero, Giulio, Marchetta, Antonio, Arrigoni, Eugenio, Mozzani, Flavio, Foti, Rosario, Sandri, Gilda, Bruzzese, Vincenzo, Paroli, Marino, Fusaro, Enrico, and Becciolini, Andrea
- Published
- 2022
- Full Text
- View/download PDF
6. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study
- Author
-
Colombo, Delia, Frassi, Micol, Pagano Mariano, Giusy, Fusaro, Enrico, Lomater, Claudia, Del Medico, Patrizia, Iannone, Florenzo, Foti, Rosario, Limonta, Massimiliano, Marchesoni, Antonio, Raffeiner, Bernd, Viapiana, Ombretta, Grassi, Walter, Grembiale, Rosa Daniela, Guggino, Giuliana, Mazzone, Antonino, Tirri, Enrico, Perricone, Roberto, Sarzi Puttini, Pier Carlo, De Vita, Salvatore, Conti, Fabrizio, Ori, Alessandra, Simoni, Lucia, Fiocchi, Martina, Orsenigo, Roberto, and Zagni, Emanuela
- Published
- 2022
- Full Text
- View/download PDF
7. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study
- Author
-
Zagni, Emanuela, Frassi, Micol, Mariano, Giuseppa Pagano, Fusaro, Enrico, Lomater, Claudia, Del Medico, Patrizia, Iannone, Florenzo, Foti, Rosario, Limonta, Massimiliano, Marchesoni, Antonio, Raffeiner, Bernd, Viapiana, Ombretta, Grassi, Walter, Grembiale, Rosa Daniela, Guggino, Giuliana, Mazzone, Antonino, Tirri, Enrico, Perricone, Roberto, Sarzi Puttini, Pier Carlo, De Vita, Salvatore, Conti, Fabrizio, Zullo, Alessandro, Simoni, Lucia, Fiocchi, Martina, Orsenigo, Roberto, and Colombo, Delia
- Published
- 2022
- Full Text
- View/download PDF
8. Early echocardiographic findings in patients hospitalized for COVID-19 pneumonia: a prospective, single center study
- Author
-
Ceriani, Elisa, Marceca, Azzurra, Lanfranchi, Antonio, De Vita, Stefano, Schiavon, Riccardo, Casella, Francesco, Torzillo, Daniela, del Medico, Marta, Ruggiero, Diego, Barosi, Alberto, and Cogliati, Chiara
- Published
- 2021
- Full Text
- View/download PDF
9. POS0604 JAKi’S SURVIVAL RATE AND PREDICTORS OF DISCONTINUATION IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS
- Author
-
Larosa, M., primary, Becciolini, A., additional, Parisi, S., additional, Donato, E. DI, additional, Camellino, D., additional, Adorni, G., additional, Lucchini, G., additional, Santilli, D., additional, Fusaro, E., additional, Ditto, M. C., additional, Lo Gullo, A., additional, Paroli, M., additional, Caccavale, R., additional, Volpe, A., additional, Marchetta, A., additional, Raffeiner, B., additional, Celletti, E., additional, Penta, M. DI, additional, Sabatini, E., additional, Cipollone, F., additional, Reta, M., additional, Addimanda, O., additional, Magnani, M., additional, Visalli, E., additional, Foti, R., additional, Amato, G., additional, De Lucia, F., additional, Farina, A., additional, Girelli, F., additional, Bernardi, S., additional, Colina, M., additional, Andracco, R., additional, Mansueto, N., additional, Ferrero, G., additional, Del Medico, P., additional, Molica Colella, A., additional, Franchina, V., additional, Molica Colella, F., additional, Lumetti, F., additional, Sandri, G., additional, Salvarani, C., additional, Giuggioli, D., additional, Priora, M., additional, Serale, F., additional, Ianniello, A., additional, Nucera, V., additional, Ometto, F., additional, Giampietro, C., additional, Bravi, E., additional, Platè, I., additional, Arrigoni, E., additional, Mascella, F., additional, Focherini, M. C., additional, Bezzi, A., additional, Scolieri, P., additional, Bruzzese, V., additional, Ravagnani, V., additional, Rovera, G., additional, Fiorenza, A., additional, Vitetta, R., additional, and Ariani, A., additional
- Published
- 2024
- Full Text
- View/download PDF
10. AB0595 DIFFERENCES BETWEEN SELECTIVE AND UNSELECTIVE JAKi: RESULTS FROM A MULTICENTRIC, REAL LIFE STUDY CARRIED OUT ON PATIENTS WITH RA
- Author
-
Larosa, M., primary, Camellino, D., additional, Becciolini, A., additional, Donato, E. DI, additional, Adorni, G., additional, Lucchini, G., additional, Santilli, D., additional, Arrigoni, E., additional, Bravi, E., additional, Platè, I., additional, Bezzi, A., additional, Focherini, M. C., additional, Mascella, F., additional, Bruzzese, V., additional, Scolieri, P., additional, Parisi, S., additional, Ditto, M. C., additional, Fusaro, E., additional, Ravagnani, V., additional, Rovera, G., additional, Fiorenza, A., additional, Vitetta, R., additional, Marchetta, A., additional, Volpe, A., additional, Raffeiner, B., additional, Celletti, E., additional, Penta, M. DI, additional, Sabatini, E., additional, Cipollone, F., additional, Ometto, F., additional, Giampietro, C., additional, Nucera, V., additional, Ianniello, A., additional, Serale, F., additional, Priora, M., additional, Giuggioli, D., additional, Salvarani, C., additional, Sandri, G., additional, Lumetti, F., additional, Molica Colella, F., additional, Franchina, V., additional, Molica Colella, A., additional, Del Medico, P., additional, Caccavale, R., additional, Paroli, M., additional, Ferrero, G., additional, Mansueto, N., additional, Andracco, R., additional, Colina, M., additional, Bernardi, S., additional, Girelli, F., additional, Farina, A., additional, Foti, R., additional, De Lucia, F., additional, Amato, G., additional, Lo Gullo, A., additional, Magnani, M., additional, Addimanda, O., additional, Reta, M., additional, and Ariani, A., additional
- Published
- 2024
- Full Text
- View/download PDF
11. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
- Author
-
Pizzuti, Laura, Barba, Maddalena, Mazzotta, Marco, Krasniqi, Eriseld, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Sergi, Domenico, Marinelli, Daniele, Paoletti, Giancarlo, Tomao, Silverio, Botticelli, Andrea, Marchetti, Paolo, Tinari, Nicola, Grassadonia, Antonino, Valerio, Maria Rosaria, Mirabelli, Rosanna, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Meattini, Icro, Pistelli, Mirco, Giotta, Francesco, Lorusso, Vito, Garufi, Carlo, Russo, Antonio, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Vaccaro, Angela, Perracchio, Letizia, di Benedetto, Anna, Daralioti, Theodora, Sperduti, Isabella, De Maria, Ruggero, Di Leo, Angelo, Sanguineti, Giuseppe, Ciliberto, Gennaro, and Vici, Patrizia
- Published
- 2021
- Full Text
- View/download PDF
12. Plasmonic Modulators in Cryogenic Environment Featuring Bandwidths in Excess of 100 GHz and Reduced Plasmonic Losses.
- Author
-
Bisang, Dominik, Horst, Yannik, Thürig, Maurus, Menachery, Kiran, Koepfli, Stefan M., Kohli, Manuel, De Leo, Eva, Destraz, Marcel, Tedaldi, Valentino, Del Medico, Nino, Hoessbacher, Claudia, Baeuerle, Benedikt, Heni, Wolfgang, and Leuthold, Juerg
- Published
- 2024
- Full Text
- View/download PDF
13. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
- Author
-
Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, De Maria, Ruggero, Leonetti, Carlo, Di Leo, Angelo, Ciliberto, Gennaro, Falcioni, Rita, and Vici, Patrizia
- Published
- 2020
- Full Text
- View/download PDF
14. Pocket-size ultrasound device in cholelithiasis: diagnostic accuracy and efficacy of short-term training
- Author
-
Del Medico, Marta, Altieri, Alessandra, Carnevale-Maffè, Gabriella, Formagnana, Pietro, Casella, Francesco, Barchiesi, Marco, Bergonzi, Manuela, Vattiato, Claudia, Casazza, Giovanni, and Cogliati, Chiara
- Published
- 2018
- Full Text
- View/download PDF
15. AB1114 MUSCULOSKELETAL ULTRASOUND BASELINE ASSESSMENT IMPROVES THE RESPONSE TO APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A MULTICENTER STUDY
- Author
-
Farina, A., primary, Del Medico, P., additional, Becciolini, A., additional, Lumetti, F., additional, Visalli, E., additional, Molica Colella, F., additional, Mansueto, N., additional, Platé, I., additional, Colina, M., additional, Lucchini, G., additional, Di Donato, E., additional, Santilli, D., additional, Parisi, S., additional, Ditto, M. C., additional, Fusaro, E., additional, Amato, G., additional, De Lucia, F., additional, Foti, R., additional, Molica Colella, A., additional, Franchina, V., additional, Caccavale, R., additional, Paroli, M., additional, Scolieri, P., additional, Andracco, R., additional, Bruzzese, V., additional, Gardelli, L., additional, Ferrero, G., additional, Bravi, E., additional, Arrigoni, E., additional, Girelli, F., additional, Marchetta, A., additional, Volpe, A., additional, Ianniello, A., additional, Nucera, V., additional, Sandri, G., additional, Salvarani, C., additional, and Ariani, A., additional
- Published
- 2023
- Full Text
- View/download PDF
16. AB1101 THERAPEUTIC EFFECTS OF APREMILAST ON ENTHESITIS AND DACTYLITIS IN REAL CLINICAL SETTING: AN ITALIAN MULTICENTER STUDY
- Author
-
Lo Gullo, A., primary, Becciolini, A., additional, Parisi, S., additional, Del Medico, P., additional, Farina, A., additional, Visalli, E., additional, Molica Colella, A., additional, Lumetti, F., additional, Caccavale, R., additional, Scolieri, P., additional, Andracco, R., additional, Girelli, F., additional, Bravi, E., additional, Colina, M., additional, Volpe, A., additional, Ianniello, A., additional, Ditto, M. C., additional, Nucera, V., additional, Franchina, V., additional, Platé, I., additional, DI Donato, E., additional, Amato, G., additional, Salvarani, C., additional, Gardelli, L., additional, Lucchini, G., additional, De Lucia, F., additional, Molica Colella, F., additional, Santilli, D., additional, Mansueto, N., additional, Ferrero, G., additional, Marchetta, A., additional, Arrigoni, E., additional, Foti, R., additional, Sandri, G., additional, Bruzzese, V., additional, Paroli, M., additional, Fusaro, E., additional, and Ariani, A., additional
- Published
- 2023
- Full Text
- View/download PDF
17. AB0452 SURVIVAL RATE OF BARICITINIB IN A LARGE COHORT OF RHEUMATOID ARTHRITIS PATIENTS: ANALYSIS OF REAL-WORLD DATA
- Author
-
Parisi, S., primary, Becciolini, A., additional, Ditto, M. C., additional, Del Medico, P., additional, Farina, A., additional, Visalli, E., additional, Molica Colella, A., additional, Lumetti, F., additional, Caccavale, R., additional, Scolieri, P., additional, Andracco, R., additional, Girelli, F., additional, Bravi, E., additional, Colina, M., additional, Volpe, A., additional, Ianniello, A., additional, Nucera, V., additional, Franchina, V., additional, Platé, I., additional, DI Donato, E., additional, Amato, G., additional, Salvarani, C., additional, Gardelli, L., additional, Lucchini, G., additional, De Lucia, F., additional, Molica Colella, F., additional, Priora, M., additional, Santilli, D., additional, Mansueto, N., additional, Ferrero, G., additional, Rovera, G., additional, Fiorenza, A., additional, Vitetta, R., additional, Marchetta, A., additional, Ravagnani, V., additional, Paroli, M., additional, Bernardi, S., additional, Arrigoni, E., additional, Foti, R., additional, Sandri, G., additional, Bruzzese, V., additional, Ometto, F., additional, Bezzi, A., additional, Focherini, M. C., additional, Adorni, G., additional, Mascella, F., additional, Lo Gullo, A., additional, Bianchi, G., additional, Camellino, D., additional, Larosa, M., additional, Addimanda, O., additional, Reta, M., additional, Ariani, A., additional, and Fusaro, E., additional
- Published
- 2023
- Full Text
- View/download PDF
18. AB0481 UPADICITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: OBSERVATION FROM AN ITALIAN MULTI-CENTRIC COHORT
- Author
-
Scolieri, P., primary, Bruzzese, V., additional, Larosa, M., additional, Farina, A., additional, Becciolini, A., additional, Lo Gullo, A., additional, Girelli, F., additional, Parisi, S., additional, Bernardi, S., additional, DI Donato, E., additional, Sandri, G., additional, Salvarani, C., additional, Bianchi, G., additional, Camellino, D., additional, Lumetti, F., additional, Del Medico, P., additional, Colina, M., additional, Bravi, E., additional, Platè, I., additional, Arrigoni, E., additional, Priora, M., additional, De Lucia, F., additional, Visalli, E., additional, Foti, R., additional, Amato, G., additional, Paroli, M., additional, Caccavale, R., additional, Andracco, R., additional, Mansueto, N., additional, Ferrero, G., additional, Molica Colella, F., additional, Franchina, V., additional, Ditto, M. C., additional, Marchetta, A., additional, Santilli, D., additional, Volpe, A., additional, Ianniello, A., additional, Nucera, V., additional, Molica Colella, A., additional, Vitetta, R., additional, Fiorenza, A., additional, Lucchini, G., additional, Adorni, G., additional, Bezzi, A., additional, Focherini, M. C., additional, Mascella, F., additional, Ravagnani, V., additional, Ometto, F., additional, Fusaro, E., additional, and Ariani, A., additional
- Published
- 2023
- Full Text
- View/download PDF
19. Gene therapies in ophthalmic disease
- Author
-
Gordon, Kathleen, Del Medico, Amy, Sander, Ian, Kumar, Arvind, and Hamad, Bashar
- Published
- 2019
- Full Text
- View/download PDF
20. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
- Author
-
Pizzuti, L, Barba, M, Mazzotta, M, Krasniqi, E, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Sergi, D, Marinelli, D, Paoletti, G, Tomao, S, Botticelli, A, Marchetti, P, Tinari, N, Grassadonia, A, Valerio, M, Mirabelli, R, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Meattini, I, Pistelli, M, Giotta, F, Lorusso, V, Garufi, C, Russo, A, Cazzaniga, M, Del Medico, P, Roselli, M, Vaccaro, A, Perracchio, L, di Benedetto, A, Daralioti, T, Sperduti, I, De Maria, R, Di Leo, A, Sanguineti, G, Ciliberto, G, Vici, P, Pizzuti L., Barba M., Mazzotta M., Krasniqi E., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Sergi D., Marinelli D., Paoletti G., Tomao S., Botticelli A., Marchetti P., Tinari N., Grassadonia A., Valerio M. R., Mirabelli R., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Meattini I., Pistelli M., Giotta F., Lorusso V., Garufi C., Russo A., Cazzaniga M., Del Medico P., Roselli M., Vaccaro A., Perracchio L., di Benedetto A., Daralioti T., Sperduti I., De Maria R., Di Leo A., Sanguineti G., Ciliberto G., Vici P., Pizzuti, L, Barba, M, Mazzotta, M, Krasniqi, E, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Sergi, D, Marinelli, D, Paoletti, G, Tomao, S, Botticelli, A, Marchetti, P, Tinari, N, Grassadonia, A, Valerio, M, Mirabelli, R, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Meattini, I, Pistelli, M, Giotta, F, Lorusso, V, Garufi, C, Russo, A, Cazzaniga, M, Del Medico, P, Roselli, M, Vaccaro, A, Perracchio, L, di Benedetto, A, Daralioti, T, Sperduti, I, De Maria, R, Di Leo, A, Sanguineti, G, Ciliberto, G, Vici, P, Pizzuti L., Barba M., Mazzotta M., Krasniqi E., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Sergi D., Marinelli D., Paoletti G., Tomao S., Botticelli A., Marchetti P., Tinari N., Grassadonia A., Valerio M. R., Mirabelli R., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Meattini I., Pistelli M., Giotta F., Lorusso V., Garufi C., Russo A., Cazzaniga M., Del Medico P., Roselli M., Vaccaro A., Perracchio L., di Benedetto A., Daralioti T., Sperduti I., De Maria R., Di Leo A., Sanguineti G., Ciliberto G., and Vici P.
- Abstract
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian cancer centers were retrospectively collected and analyzed. From 2003 to 2017, 491 HER2‐positive mBC patients were included. Of these, 102 (20.7%) had been initially diagnosed as HER2-negative early BC. Estrogen and/or progesterone receptor were more expressed in patients with HER2-discordance compared to patients with HER2-concordant status (p < 0.0001 and p = 0.006, respectively). HER2-discordant tumors were characterized also by a lower rate of brain metastases (p = 0.01) and a longer disease free interval (p < 0.0001). Median overall survival was longer, although not statistically significant, in the subgroup of patients with HER2-discordant cancer with respect to patients with HER2-concordant status (140 vs 78 months, p = 0.07). Our findings suggest that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2-concordant patients.
- Published
- 2021
21. POS1027 APREMILAST EFFICACY IN REAL WORLD SETTINGS: RESULTS FROM AN ITALIAN MULTI-CENTER OBSERVATIONAL STUDY.
- Author
-
Ariani, A., primary, Parisi, S., additional, Del Medico, P., additional, Farina, A., additional, Visalli, E., additional, Molica Colella, A., additional, Lumetti, F., additional, Caccavale, R., additional, Scolieri, P., additional, Andracco, R., additional, Girelli, F., additional, Bravi, E., additional, Colina, M., additional, Franchina, V., additional, Platé, I., additional, DI Donato, E., additional, Amato, G., additional, Salvarani, C., additional, De Lucia, F., additional, Santilli, D., additional, Arrigoni, E., additional, Mozzani, F., additional, Foti, R., additional, Sandri, G., additional, Bruzzese, V., additional, Paroli, M., additional, Fusaro, E., additional, and Becciolini, A., additional
- Published
- 2022
- Full Text
- View/download PDF
22. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
- Author
-
Bon, G, Pizzuti, L, Laquintana, V, Loria, R, Porru, M, Marchio, C, Krasniqi, E, Barba, M, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Barchiesi, G, Mazzotta, M, Marinelli, D, Tomao, S, Marchetti, P, Valerio, M, Mirabelli, R, Russo, A, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Giotta, F, Garufi, C, Cazzaniga, M, Del Medico, P, Roselli, M, Sanguineti, G, Sperduti, I, Sapino, A, De Maria, R, Leonetti, C, Di Leo, A, Ciliberto, G, Falcioni, R, Vici, P, Bon G., Pizzuti L., Laquintana V., Loria R., Porru M., Marchio C., Krasniqi E., Barba M., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Barchiesi G., Mazzotta M., Marinelli D., Tomao S., Marchetti P., Valerio M. R., Mirabelli R., Russo A., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Giotta F., Garufi C., Cazzaniga M., Del Medico P., Roselli M., Sanguineti G., Sperduti I., Sapino A., De Maria R., Leonetti C., Di Leo A., Ciliberto G., Falcioni R., Vici P., Bon, G, Pizzuti, L, Laquintana, V, Loria, R, Porru, M, Marchio, C, Krasniqi, E, Barba, M, Maugeri-Sacca, M, Gamucci, T, Berardi, R, Livi, L, Ficorella, C, Natoli, C, Cortesi, E, Generali, D, La Verde, N, Cassano, A, Bria, E, Moscetti, L, Michelotti, A, Adamo, V, Zamagni, C, Tonini, G, Barchiesi, G, Mazzotta, M, Marinelli, D, Tomao, S, Marchetti, P, Valerio, M, Mirabelli, R, Russo, A, Fabbri, M, D'Ostilio, N, Veltri, E, Corsi, D, Garrone, O, Paris, I, Sarobba, G, Giotta, F, Garufi, C, Cazzaniga, M, Del Medico, P, Roselli, M, Sanguineti, G, Sperduti, I, Sapino, A, De Maria, R, Leonetti, C, Di Leo, A, Ciliberto, G, Falcioni, R, Vici, P, Bon G., Pizzuti L., Laquintana V., Loria R., Porru M., Marchio C., Krasniqi E., Barba M., Maugeri-Sacca M., Gamucci T., Berardi R., Livi L., Ficorella C., Natoli C., Cortesi E., Generali D., La Verde N., Cassano A., Bria E., Moscetti L., Michelotti A., Adamo V., Zamagni C., Tonini G., Barchiesi G., Mazzotta M., Marinelli D., Tomao S., Marchetti P., Valerio M. R., Mirabelli R., Russo A., Fabbri M. A., D'Ostilio N., Veltri E., Corsi D., Garrone O., Paris I., Sarobba G., Giotta F., Garufi C., Cazzaniga M., Del Medico P., Roselli M., Sanguineti G., Sperduti I., Sapino A., De Maria R., Leonetti C., Di Leo A., Ciliberto G., Falcioni R., and Vici P.
- Abstract
Background: HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to different drugs sequences including pertuzumab and T-DM1 in HER2 positive cell lines. Methods: The biology of HER2 was investigated in vitro through sequential exposure of resistant HER2 + breast cancer cell lines to trastuzumab, pertuzumab, and their combination. In vitro experiments were paralleled by the analysis of data from 555 HER2 + ABC patients treated with T-DM1 and evaluation of T-DM1 efficacy in the 371 patients who received it in second line. Survival estimates were graphically displayed in Kaplan Meier curves, compared by log rank test and, when possibile, confirmed in multivariate models. Results: We herein show evidence of lower activity of T-DM1 in two HER2+ breast cancer cell lines resistant to trastuzumab+pertuzumab, as compared to trastuzumab-resistant cells. Lower T-DM1 efficacy was associated with a marked reduction of HER2 expression on the cell membrane and its nuclear translocation. HER2 downregulation at the membrane level was confirmed in biopsies of four trastuzumab/pertuzumab-pretreated patients. Among the 371 patients treated with second-line T-DM1, median overall survival (mOS) from diagnosis of advanced disease and median progression-free survival to second-line treatment (mPFS2) were 52 and 6 months in 177 patients who received trastuzumab/pertuzumab in f
- Published
- 2020
23. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
- Author
-
Pizzuti, L, Krasniqi, E, Barchiesi, G, Della Giulia, M, Izzo, F, Sanguineti, G, Marchetti, P, Mazzotta, M, Giusti, R, Botticelli, A, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Iezzi, L, Tomao, S, Tomao, F, Tonini, G, Santini, D, Astone, A, Michelotti, A, De Angelis, C, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Rossi, E, Cazzaniga, M, Moscetti, L, Omarini, C, Piacentini, F, Fabbri, M, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Samaritani, R, Garufi, C, Barni, S, Mirabelli, R, Sarmiento, R, Veltri, E, D'Auria, G, Paris, I, Giotta, F, Lorusso, V, Cardillo, F, Landucci, E, Mauri, M, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Berardi, R, Pistelli, M, Fiorio, E, Cannita, K, Sini, V, D'Ostilio, N, Foglietta, J, Greco, F, Zamagni, C, Garrone, O, Di Cocco, B, Baldini, E, Livi, L, Desideri, I, Meattini, I, Sarobba, G, Del Medico, P, De Tursi, M, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Sperduti, I, Villa, A, Barba, M, Di Leo, A, Vici, P, Pizzuti L., Krasniqi E., Barchiesi G., Della Giulia M., Izzo F., Sanguineti G., Marchetti P., Mazzotta M., Giusti R., Botticelli A., Gamucci T., Natoli C., Grassadonia A., Tinari N., Iezzi L., Tomao S., Tomao F., Tonini G., Santini D., Astone A., Michelotti A., De Angelis C., Mentuccia L., Vaccaro A., Magnolfi E., Gelibter A., Magri V., Cortesi E., D'Onofrio L., Cassano A., Rossi E., Cazzaniga M., Moscetti L., Omarini C., Piacentini F., Fabbri M. A., Scinto A. F., Corsi D., Carbognin L., Bria E., La Verde N., Samaritani R., Garufi C., Barni S., Mirabelli R., Sarmiento R., Veltri E. M., D'Auria G., Paris I., Giotta F., Lorusso V., Cardillo F., Landucci E., Mauri M., Ficorella C., Roselli M., Adamo V., Ricciardi G. R. R., Russo A., Berardi R., Pistelli M., Fiorio E., Cannita K., Sini V., D'Ostilio N., Foglietta J., Greco F., Zamagni C., Garrone O., Di Cocco B., Baldini E., Livi L., Desideri I., Meattini I., Sarobba G., Del Medico P., De Tursi M., Generali D., De Maria R., Risi E., Ciliberto G., Sperduti I., Villa A., Barba M., Di Leo A., Vici P., Pizzuti, L, Krasniqi, E, Barchiesi, G, Della Giulia, M, Izzo, F, Sanguineti, G, Marchetti, P, Mazzotta, M, Giusti, R, Botticelli, A, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Iezzi, L, Tomao, S, Tomao, F, Tonini, G, Santini, D, Astone, A, Michelotti, A, De Angelis, C, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Rossi, E, Cazzaniga, M, Moscetti, L, Omarini, C, Piacentini, F, Fabbri, M, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Samaritani, R, Garufi, C, Barni, S, Mirabelli, R, Sarmiento, R, Veltri, E, D'Auria, G, Paris, I, Giotta, F, Lorusso, V, Cardillo, F, Landucci, E, Mauri, M, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Berardi, R, Pistelli, M, Fiorio, E, Cannita, K, Sini, V, D'Ostilio, N, Foglietta, J, Greco, F, Zamagni, C, Garrone, O, Di Cocco, B, Baldini, E, Livi, L, Desideri, I, Meattini, I, Sarobba, G, Del Medico, P, De Tursi, M, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Sperduti, I, Villa, A, Barba, M, Di Leo, A, Vici, P, Pizzuti L., Krasniqi E., Barchiesi G., Della Giulia M., Izzo F., Sanguineti G., Marchetti P., Mazzotta M., Giusti R., Botticelli A., Gamucci T., Natoli C., Grassadonia A., Tinari N., Iezzi L., Tomao S., Tomao F., Tonini G., Santini D., Astone A., Michelotti A., De Angelis C., Mentuccia L., Vaccaro A., Magnolfi E., Gelibter A., Magri V., Cortesi E., D'Onofrio L., Cassano A., Rossi E., Cazzaniga M., Moscetti L., Omarini C., Piacentini F., Fabbri M. A., Scinto A. F., Corsi D., Carbognin L., Bria E., La Verde N., Samaritani R., Garufi C., Barni S., Mirabelli R., Sarmiento R., Veltri E. M., D'Auria G., Paris I., Giotta F., Lorusso V., Cardillo F., Landucci E., Mauri M., Ficorella C., Roselli M., Adamo V., Ricciardi G. R. R., Russo A., Berardi R., Pistelli M., Fiorio E., Cannita K., Sini V., D'Ostilio N., Foglietta J., Greco F., Zamagni C., Garrone O., Di Cocco B., Baldini E., Livi L., Desideri I., Meattini I., Sarobba G., Del Medico P., De Tursi M., Generali D., De Maria R., Risi E., Ciliberto G., Sperduti I., Villa A., Barba M., Di Leo A., and Vici P.
- Abstract
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival at first-line (mPFS1) was 12 months. Pertuzumab as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T-DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs; p = 0.17), while a trend emerged for tumors with one HR (p = 0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p = 0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T-DM1 in second-line after pertuzumab were significantly lower compared to pertuzumab-naïve patients (p = 0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p = 0.02 and p = 0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-related outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor pathways in HER2-positive (mbc) patients
- Published
- 2020
24. Epidemiology of Clostridium difficile-associated disease in internal medicine wards in northern Italy
- Author
-
Mellace, Luca, Consonni, Dario, Jacchetti, Gaia, Del Medico, Marta, Colombo, Riccardo, Velati, Marta, Formica, Simone, Cappellini, Maria Domenica, Castaldi, Silvana, and Fabio, Giovanna
- Published
- 2013
- Full Text
- View/download PDF
25. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer
- Author
-
Di Lauro, Luigi, Vici, Patrizia, Del Medico, Pietro, Laudadio, Lucio, Tomao, Silverio, Giannarelli, Diana, Pizzuti, Laura, Sergi, Domenico, Barba, Maddalena, and Maugeri-Saccà, Marcello
- Published
- 2013
- Full Text
- View/download PDF
26. A long story begun with a simple sore throat
- Author
-
Pisano, Giuseppina, Bonara, Paola, Rietti, Paolo, Airaghi, Lorena, Sinigaglia, Luigi, Boccoli, Giovanni, Burdick, Larry, del Medico, Marta, Pulixi, Edoardo, Silini, Fabio, Gandolfi, Alessandra, and Fargion, Silvia
- Published
- 2010
- Full Text
- View/download PDF
27. Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice
- Author
-
Costantino, Giorgio, Rusconi, Anna Maria, Duca, Pier Giorgio, Guzzetti, Stefano, Bossi, Ilaria, Del Medico, Marta, Pisano, Giuseppina, Bulgheroni, Mara, Solbiati, Monica, Furlan, Raffaello, and Montano, Nicola
- Published
- 2009
- Full Text
- View/download PDF
28. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
- Author
-
Pizzuti, L., Barba, M., Mazzotta, M., Krasniqi, E., Maugeri-Sacca, M., Gamucci, T., Berardi, R., Livi, L., Ficorella, C., Natoli, C., Cortesi, E., Generali, D., La Verde, N., Cassano, A., Bria, Emilio, Moscetti, L., Michelotti, A., Adamo, V., Zamagni, C., Tonini, G., Sergi, D., Marinelli, D., Paoletti, G., Tomao, S., Botticelli, A., Marchetti, P., Tinari, N., Grassadonia, A., Valerio, M. R., Mirabelli, R., Fabbri, M. A., D'Ostilio, N., Veltri, E., Corsi, Domenico Cristiano, Garrone, O., Paris, Ida, Sarobba, G., Meattini, I., Pistelli, M., Giotta, F., Lorusso, V., Garufi, C., Russo, A., Cazzaniga, M., Del Medico, P., Roselli, M., Vaccaro, A., Perracchio, L., di Benedetto, A., Daralioti, T., Sperduti, I., De Maria Marchiano, Ruggero, Di Leo, A., Sanguineti, G., Ciliberto, G., Vici, P., Bria E. (ORCID:0000-0002-2333-704X), Corsi D., Paris I., De Maria R. (ORCID:0000-0003-2255-0583), Pizzuti, L., Barba, M., Mazzotta, M., Krasniqi, E., Maugeri-Sacca, M., Gamucci, T., Berardi, R., Livi, L., Ficorella, C., Natoli, C., Cortesi, E., Generali, D., La Verde, N., Cassano, A., Bria, Emilio, Moscetti, L., Michelotti, A., Adamo, V., Zamagni, C., Tonini, G., Sergi, D., Marinelli, D., Paoletti, G., Tomao, S., Botticelli, A., Marchetti, P., Tinari, N., Grassadonia, A., Valerio, M. R., Mirabelli, R., Fabbri, M. A., D'Ostilio, N., Veltri, E., Corsi, Domenico Cristiano, Garrone, O., Paris, Ida, Sarobba, G., Meattini, I., Pistelli, M., Giotta, F., Lorusso, V., Garufi, C., Russo, A., Cazzaniga, M., Del Medico, P., Roselli, M., Vaccaro, A., Perracchio, L., di Benedetto, A., Daralioti, T., Sperduti, I., De Maria Marchiano, Ruggero, Di Leo, A., Sanguineti, G., Ciliberto, G., Vici, P., Bria E. (ORCID:0000-0002-2333-704X), Corsi D., Paris I., and De Maria R. (ORCID:0000-0003-2255-0583)
- Abstract
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian cancer centers were retrospectively collected and analyzed. From 2003 to 2017, 491 HER2‐positive mBC patients were included. Of these, 102 (20.7%) had been initially diagnosed as HER2-negative early BC. Estrogen and/or progesterone receptor were more expressed in patients with HER2-discordance compared to patients with HER2-concordant status (p < 0.0001 and p = 0.006, respectively). HER2-discordant tumors were characterized also by a lower rate of brain metastases (p = 0.01) and a longer disease free interval (p < 0.0001). Median overall survival was longer, although not statistically significant, in the subgroup of patients with HER2-discordant cancer with respect to patients with HER2-concordant status (140 vs 78 months, p = 0.07). Our findings suggest that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2-concordant patients.
- Published
- 2021
29. Raynaud’s phenomenon in undifferentiated connective tissue disease (UCTD)
- Author
-
De Angelis, Rossella, Cerioni, Angela, Del Medico, Patrizia, and Blasetti, Patrizia
- Published
- 2005
- Full Text
- View/download PDF
30. Raynaud’s Phenomenon: Clinical Spectrum Of 118 Patients
- Author
-
De Angelis, Rossella, Del Medico, Patrizia, Blasetti, Patrizia, and Cervini, Claudio
- Published
- 2003
- Full Text
- View/download PDF
31. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer
- Author
-
De Angelis, R., Bugatti, L., Cerioni, A., Del Medico, P., and Filosa, G.
- Published
- 2003
- Full Text
- View/download PDF
32. AB0481 UPADICITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: OBSERVATION FROM AN ITALIAN MULTI-CENTRIC COHORT
- Author
-
Scolieri, P., Bruzzese, V., Larosa, M., Farina, A., Becciolini, A., Lo Gullo, A., Girelli, F., Parisi, S., Bernardi, S., DI Donato, E., Sandri, G., Salvarani, C., Bianchi, G., Camellino, D., Lumetti, F., Del Medico, P., Colina, M., Bravi, E., Platè, I., Arrigoni, E., Priora, M., De Lucia, F., Visalli, E., Foti, R., Amato, G., Paroli, M., Caccavale, R., Andracco, R., Mansueto, N., Ferrero, G., Molica Colella, F., Franchina, V., Ditto, M.C., Marchetta, A., Santilli, D., Volpe, A., Ianniello, A., Nucera, V., Molica Colella, A., Vitetta, R., Fiorenza, A., Lucchini, G., Adorni, G., Bezzi, A., Focherini, M.C., Mascella, F., Ravagnani, V., Ometto, F., Fusaro, E., and Ariani, A.
- Published
- 2023
- Full Text
- View/download PDF
33. AB0386 DIFFERENCES BETWEEN JAKIS-NAIVE AND JAKIS-NOT NAIVE PATIENTS IN A REAL LIFE CLINICAL SETTING: DATA FROM AN PROSPECTIVE MULTICENTRIC ITALIAN STUDY.
- Author
-
Larosa, M., Becciolini, A., Bravi, E., Camellino, D., Platé, I., Arrigoni, E., Ometto, F., DI Donato, E., Adorni, G., Lucchini, G., Santilli, D., Bezzi, A., Focherini, M.C., Mascella, F., Bruzzese, V., Scolieri, P., Parisi, S., Fusaro, E., Ditto, M.C., Ravagnani, V., Sandri, G., Salvarani, C., Priora, M., Paroli, M., Caccavale, R., Andracco, R., Mansueto, N., Colina, M., Reta, M., Addimanda, O., Lo Gullo, A., Visalli, E., Foti, R., Amato, G., De Lucia, F., Farina, A., Girelli, F., Del Medico, P., Molica Colella, A., Franchina, V., Molica Colella, F., Lumetti, F., Ianniello, A., Nucera, V., Vitetta, R., Fiorenza, A., Rovera, G., Volpe, A., Ferrero, G., Marchetta, A., Bernardi, S., Bianchi, G., and Ariani, A.
- Published
- 2023
- Full Text
- View/download PDF
34. AB0452 SURVIVAL RATE OF BARICITINIB IN A LARGE COHORT OF RHEUMATOID ARTHRITIS PATIENTS: ANALYSIS OF REAL-WORLD DATA
- Author
-
Parisi, S., Becciolini, A., Ditto, M.C., Del Medico, P., Farina, A., Visalli, E., Molica Colella, A., Lumetti, F., Caccavale, R., Scolieri, P., Andracco, R., Girelli, F., Bravi, E., Colina, M., Volpe, A., Ianniello, A., Nucera, V., Franchina, V., Platé, I., DI Donato, E., Amato, G., Salvarani, C., Gardelli, L., Lucchini, G., De Lucia, F., Molica Colella, F., Priora, M., Santilli, D., Mansueto, N., Ferrero, G., Rovera, G., Fiorenza, A., Vitetta, R., Marchetta, A., Ravagnani, V., Paroli, M., Bernardi, S., Arrigoni, E., Foti, R., Sandri, G., Bruzzese, V., Ometto, F., Bezzi, A., Focherini, M.C., Adorni, G., Mascella, F., Lo Gullo, A., Bianchi, G., Camellino, D., Larosa, M., Addimanda, O., Reta, M., Ariani, A., and Fusaro, E.
- Published
- 2023
- Full Text
- View/download PDF
35. AB0302 DISCONTINUATION RATE AND PREDICTORS OF JAKI DISCONTINUATION IN A REAL LIFE COHORT: RESULTS FROM A MULTICENTRIC ITALIAN STUDY ON 864 PATIENTS WITH RA
- Author
-
Larosa, M., Ariani, A., Camellino, D., Becciolini, A., Bianchi, G., Di Donato, E., Adorni, G., Santilli, D., Lucchini, G., Reta, M., Addimanda, O., Lo Gullo, A., Visalli, E., Foti, R., Amato, G., De Lucia, F., Farina, A., Girelli, F., Bernardi, S., Ferrero, G., Andracco, R., Paroli, M., Mansueto, N., Caccavale, R., Del Medico, P., Molica Colella, A., Franchina, V., Molica Colella, F., Lumetti, F., Sandri, G., Salvarani, C., Priora, M., Ianniello, A., Nucera, V., Ometto, F., Platé, I., Arrigoni, E., Bezzi, A., Focherini, M.C., Mascella, F., Bruzzese, V., Scolieri, P., Parisi, S., Ditto, M.C., Fusaro, E., Ravagnani, V., Vitetta, R., Fiorenza, A., Rovera, G., Volpe, A., Marchetta, A., Colina, M., and Bravi, E.
- Published
- 2023
- Full Text
- View/download PDF
36. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study
- Author
-
Sebastiani, M, Manfredi, A, Vukatana, G, Moscatelli, S, Riato, L, Bocci, M, Iudici, M, Principato, A, Mazzuca, S, Del Medico, P, De Angelis, R, DʼAmico, R, Vicini, R, Colaci, M, and Ferri, C
- Published
- 2012
- Full Text
- View/download PDF
37. PBI57 Effectiveness of Biologic Treatments for Psoriatic Arthritis in Italy: Preliminary Results of the Chronos Study
- Author
-
Colombo, D., primary, Simoni, L., additional, Ori, A., additional, Fiocchi, M., additional, Frassi, M., additional, Pagano Mariano, G., additional, Fusaro, E., additional, Lomater, C., additional, Del Medico, P., additional, Iannone, F., additional, Foti, R., additional, Limonta, M., additional, Marchesoni, A., additional, Raffeiner, B., additional, Viapiana, O., additional, Grassi, W., additional, Grembiale, R.D., additional, Guggino, G., additional, Faggioli, P., additional, Tirri, E., additional, Perricone, R., additional, Sarzi Puttini, P.C., additional, De Vita, S., additional, Conti, F., additional, and Zagni, E., additional
- Published
- 2020
- Full Text
- View/download PDF
38. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
- Author
-
Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, Vici, Patrizia, Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, and Vici, Patrizia
- Abstract
Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
- Published
- 2020
39. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
- Author
-
Bon, G., Pizzuti, L., Laquintana, V., Loria, R., Porru, M., Marchio, C., Krasniqi, E., Barba, M., Maugeri-Sacca, M., Gamucci, T., Berardi, R., Livi, L., Ficorella, C., Natoli, C., Cortesi, E., Generali, D., La Verde, N., Cassano, Alessandra, Bria, Emilio, Moscetti, L., Michelotti, A., Adamo, V., Zamagni, C., Tonini, G., Barchiesi, G., Mazzotta, M., Marinelli, D., Tomao, S., Marchetti, P., Valerio, M. R., Mirabelli, R., Russo, A., Fabbri, M. A., D'Ostilio, N., Veltri, E., Corsi, D., Garrone, O., Paris, I., Sarobba, G., Giotta, F., Garufi, C., Cazzaniga, M., Del Medico, P., Roselli, M., Sanguineti, G., Sperduti, I., Sapino, A., De Maria Marchiano, Ruggero, Leonetti, C., Di Leo, A., Ciliberto, G., Falcioni, R., Vici, P., Cassano A. (ORCID:0000-0002-3311-7163), Bria E. (ORCID:0000-0002-2333-704X), De Maria R. (ORCID:0000-0003-2255-0583), Bon, G., Pizzuti, L., Laquintana, V., Loria, R., Porru, M., Marchio, C., Krasniqi, E., Barba, M., Maugeri-Sacca, M., Gamucci, T., Berardi, R., Livi, L., Ficorella, C., Natoli, C., Cortesi, E., Generali, D., La Verde, N., Cassano, Alessandra, Bria, Emilio, Moscetti, L., Michelotti, A., Adamo, V., Zamagni, C., Tonini, G., Barchiesi, G., Mazzotta, M., Marinelli, D., Tomao, S., Marchetti, P., Valerio, M. R., Mirabelli, R., Russo, A., Fabbri, M. A., D'Ostilio, N., Veltri, E., Corsi, D., Garrone, O., Paris, I., Sarobba, G., Giotta, F., Garufi, C., Cazzaniga, M., Del Medico, P., Roselli, M., Sanguineti, G., Sperduti, I., Sapino, A., De Maria Marchiano, Ruggero, Leonetti, C., Di Leo, A., Ciliberto, G., Falcioni, R., Vici, P., Cassano A. (ORCID:0000-0002-3311-7163), Bria E. (ORCID:0000-0002-2333-704X), and De Maria R. (ORCID:0000-0003-2255-0583)
- Abstract
Background: HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to different drugs sequences including pertuzumab and T-DM1 in HER2 positive cell lines. Methods: The biology of HER2 was investigated in vitro through sequential exposure of resistant HER2 + breast cancer cell lines to trastuzumab, pertuzumab, and their combination. In vitro experiments were paralleled by the analysis of data from 555 HER2 + ABC patients treated with T-DM1 and evaluation of T-DM1 efficacy in the 371 patients who received it in second line. Survival estimates were graphically displayed in Kaplan Meier curves, compared by log rank test and, when possibile, confirmed in multivariate models. Results: We herein show evidence of lower activity of T-DM1 in two HER2+ breast cancer cell lines resistant to trastuzumab+pertuzumab, as compared to trastuzumab-resistant cells. Lower T-DM1 efficacy was associated with a marked reduction of HER2 expression on the cell membrane and its nuclear translocation. HER2 downregulation at the membrane level was confirmed in biopsies of four trastuzumab/pertuzumab-pretreated patients. Among the 371 patients treated with second-line T-DM1, median overall survival (mOS) from diagnosis of advanced disease and median progression-free survival to second-line treatment (mPFS2) were 52 and 6 months in 177 patients who received trastuzumab/pertuzumab in f
- Published
- 2020
40. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
- Author
-
Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., Kayal, R., Sanguineti, G., Marchetti, P., Botticelli, A., Marinelli, D., Gamucci, T., Natoli, C., Grassadonia, A., Tinari, N., Tomao, S., Tonini, Gerolamo, Santini, D., Michelotti, A., Mentuccia, L., Vaccaro, Ascanio Giuseppe, Magnolfi, E., Gelibter, A., Magri, V., Cortesi, E., D'Onofrio, L., Cassano, Alessandra, Cazzaniga, M., Moscetti, L., Fabbri, A., Scinto, A. F., Corsi, Domenico Cristiano, Carbognin, L., Bria, Emilio, La Verde, N., Garufi, C., Di Stefano, P., Mirabelli, R., Veltri, E., Paris, Ida, Giotta, F., Lorusso, V., Landucci, E., Ficorella, C., Roselli, M., Adamo, V., Ricciardi, Walter, Russo, A., Valerio, M. R., Berardi, R., Pistelli, M., Cannita, K., Zamagni, C., Garrone, O., Baldini, E., Livi, L., Meattini, I., Del Medico, P., Generali, Daniele, De Maria Marchiano, Ruggero, Risi, E., Ciliberto, G., Villa, Angela Ida, Sperduti, I., Mazzotta, M., Barba, M., Giordano, Alessandro, Vici, P., Tonini G., Vaccaro A., Cassano A. (ORCID:0000-0002-3311-7163), Corsi D., Bria E. (ORCID:0000-0002-2333-704X), Paris I., Ricciardi G. (ORCID:0000-0002-5655-688X), Generali D. (ORCID:0000-0003-2480-3855), De Maria R. (ORCID:0000-0003-2255-0583), Villa A. (ORCID:0000-0003-0679-334X), Giordano A. (ORCID:0000-0002-6978-0880), Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., Kayal, R., Sanguineti, G., Marchetti, P., Botticelli, A., Marinelli, D., Gamucci, T., Natoli, C., Grassadonia, A., Tinari, N., Tomao, S., Tonini, Gerolamo, Santini, D., Michelotti, A., Mentuccia, L., Vaccaro, Ascanio Giuseppe, Magnolfi, E., Gelibter, A., Magri, V., Cortesi, E., D'Onofrio, L., Cassano, Alessandra, Cazzaniga, M., Moscetti, L., Fabbri, A., Scinto, A. F., Corsi, Domenico Cristiano, Carbognin, L., Bria, Emilio, La Verde, N., Garufi, C., Di Stefano, P., Mirabelli, R., Veltri, E., Paris, Ida, Giotta, F., Lorusso, V., Landucci, E., Ficorella, C., Roselli, M., Adamo, V., Ricciardi, Walter, Russo, A., Valerio, M. R., Berardi, R., Pistelli, M., Cannita, K., Zamagni, C., Garrone, O., Baldini, E., Livi, L., Meattini, I., Del Medico, P., Generali, Daniele, De Maria Marchiano, Ruggero, Risi, E., Ciliberto, G., Villa, Angela Ida, Sperduti, I., Mazzotta, M., Barba, M., Giordano, Alessandro, Vici, P., Tonini G., Vaccaro A., Cassano A. (ORCID:0000-0002-3311-7163), Corsi D., Bria E. (ORCID:0000-0002-2333-704X), Paris I., Ricciardi G. (ORCID:0000-0002-5655-688X), Generali D. (ORCID:0000-0003-2480-3855), De Maria R. (ORCID:0000-0003-2255-0583), Villa A. (ORCID:0000-0003-0679-334X), and Giordano A. (ORCID:0000-0002-6978-0880)
- Abstract
Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
- Published
- 2020
41. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
- Author
-
Pizzuti, L., Krasniqi, E., Barchiesi, G., Della Giulia, M., Izzo, F., Sanguineti, G., Marchetti, P., Mazzotta, M., Giusti, R., Botticelli, A., Gamucci, T., Natoli, C., Grassadonia, A., Tinari, N., Iezzi, L., Tomao, S., Tomao, F., Tonini, G., Santini, D., Astone, Antonio, Michelotti, A., De Angelis, C., Mentuccia, L., Vaccaro, A., Magnolfi, E., Gelibter, A., Magri, V., Cortesi, E., D'Onofrio, L., Cassano, Alessandra, Rossi, E., Cazzaniga, M., Moscetti, L., Omarini, C., Piacentini, F., Fabbri, M. A., Scinto, A. F., Corsi, D., Carbognin, L., Bria, Emilio, La Verde, N., Samaritani, R., Garufi, C., Barni, S., Mirabelli, R., Sarmiento, R., Veltri, E. M., D'Auria, G., Paris, I., Giotta, F., Lorusso, V., Cardillo, F., Landucci, E., Mauri, M., Ficorella, C., Roselli, M., Adamo, V., Ricciardi, G. R. R., Russo, A., Berardi, R., Pistelli, M., Fiorio, E., Cannita, K., Sini, V., D'Ostilio, N., Foglietta, J., Greco, F., Zamagni, C., Garrone, O., Di Cocco, B., Baldini, E., Livi, L., Desideri, I., Meattini, I., Sarobba, G., Del Medico, P., De Tursi, M., Generali, D., De Maria Marchiano, Ruggero, Risi, E., Ciliberto, G., Sperduti, I., Villa, A., Barba, M., Di Leo, A., Vici, P., Astone A. (ORCID:0000-0001-9572-309X), Cassano A. (ORCID:0000-0002-3311-7163), Bria E. (ORCID:0000-0002-2333-704X), De Maria R. (ORCID:0000-0003-2255-0583), Pizzuti, L., Krasniqi, E., Barchiesi, G., Della Giulia, M., Izzo, F., Sanguineti, G., Marchetti, P., Mazzotta, M., Giusti, R., Botticelli, A., Gamucci, T., Natoli, C., Grassadonia, A., Tinari, N., Iezzi, L., Tomao, S., Tomao, F., Tonini, G., Santini, D., Astone, Antonio, Michelotti, A., De Angelis, C., Mentuccia, L., Vaccaro, A., Magnolfi, E., Gelibter, A., Magri, V., Cortesi, E., D'Onofrio, L., Cassano, Alessandra, Rossi, E., Cazzaniga, M., Moscetti, L., Omarini, C., Piacentini, F., Fabbri, M. A., Scinto, A. F., Corsi, D., Carbognin, L., Bria, Emilio, La Verde, N., Samaritani, R., Garufi, C., Barni, S., Mirabelli, R., Sarmiento, R., Veltri, E. M., D'Auria, G., Paris, I., Giotta, F., Lorusso, V., Cardillo, F., Landucci, E., Mauri, M., Ficorella, C., Roselli, M., Adamo, V., Ricciardi, G. R. R., Russo, A., Berardi, R., Pistelli, M., Fiorio, E., Cannita, K., Sini, V., D'Ostilio, N., Foglietta, J., Greco, F., Zamagni, C., Garrone, O., Di Cocco, B., Baldini, E., Livi, L., Desideri, I., Meattini, I., Sarobba, G., Del Medico, P., De Tursi, M., Generali, D., De Maria Marchiano, Ruggero, Risi, E., Ciliberto, G., Sperduti, I., Villa, A., Barba, M., Di Leo, A., Vici, P., Astone A. (ORCID:0000-0001-9572-309X), Cassano A. (ORCID:0000-0002-3311-7163), Bria E. (ORCID:0000-0002-2333-704X), and De Maria R. (ORCID:0000-0003-2255-0583)
- Abstract
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival at first-line (mPFS1) was 12 months. Pertuzumab as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T-DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs; p = 0.17), while a trend emerged for tumors with one HR (p = 0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p = 0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T-DM1 in second-line after pertuzumab were significantly lower compared to pertuzumab-naïve patients (p = 0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p = 0.02 and p = 0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-related outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor pathways in HER2-positive (mbc) patients.
- Published
- 2020
42. Can we extend thrombolysis indications for acute ischaemic stroke? The IST-3 study
- Author
-
Del Medico, Marta, Bonura, Antonella, and Gruppo di Autoformazione Metodologica (GrAM)
- Published
- 2013
- Full Text
- View/download PDF
43. Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study
- Author
-
Di Lauro, L, Pizzuti, L, Barba, M, Sergi, Daniele, Sperduti, I, Mottolese, M, Del Medico, P, Belli, F, Vici, P, De Maria Marchiano, Ruggero, R, and Maugeri-Saccà, M.
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Breast Neoplasms, Male ,Young Adult ,Metastatic disease ,Stable Disease ,Breast cancer ,Male breast cancer, Metastatic disease, Chemotherapy, Anthracycline-containing regimens, Anthracycline- free regimens ,Settore MED/04 - PATOLOGIA GENERALE ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,medicine ,Anthracycline- free regimens ,Humans ,Chemotherapy ,Neoplasm Metastasis ,Young adult ,Aged ,Retrospective Studies ,Antitumor activity ,Anthracycline-free regimens ,business.industry ,Endocrine therapy ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Male breast cancer ,Anthracycline-containing regimens ,Treatment Outcome ,business ,Research Article - Abstract
Background The role of chemotherapy in the treatment of metastatic male breast cancer patients remains unknown, and the only available evidence stem from small, retrospective series evaluating outdated drugs and/or regimens. Methods In this retrospective study we evaluated the activity of polychemotherapy, consisting of three-drug (anthracycline-containing and anthracycline-free) regimens, as a first-line therapy for metastatic male breast cancer patients who had received at least one prior endocrine therapy. Results Fifty patients treated between 1978 and 2013 were included in the present analysis. Regarding best response, we recorded 1 (2%) complete response and 27 (54%) partial responses, for an overall response rate of 56% (95% CI, 42.2-69.8). Considering stable disease, the disease control rate was 84%. Median progression-free survival was 7.2 months (95% CI, 5.9-8.5), and median overall survival was 14.2 months (95% CI, 12.2-16.2). Albeit we observed some differences for all the outcomes explored when comparing anthracycline-containing and anthracycline-free regimens, they were not statistically significant. Conclusions Chemotherapy, consisting in both anthracycline-containing and anthracycline-free regimens, showed encouraging antitumor activity in metastatic male breast cancer patients previously treated with endocrine therapy.
- Published
- 2015
44. UPADICITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: OBSERVATION FROM AN ITALIAN MULTICENTRIC COHORT.
- Author
-
Scolieri, P., Bruzzese, V., Larosa, M., Farina, A., Becciolini, A., Gullo, A. Lo, Girelli, F., Parisi, S., Bernardi, S., DI Donato, E., Sandri, G., Salvarani, C., Bianchi, G., Camellino, D., Lumetti, F., Del Medico, P., Colina, M., Bravi, E., Platè, I., and Arrigoni, E.
- Published
- 2023
- Full Text
- View/download PDF
45. SURVIVAL RATE OF BARICITINIB IN A LARGE COHORT OF RHEUMATOID ARTHRITIS PATIENTS: ANALYSIS OF REAL-WORLD DATA.
- Author
-
Parisi, S., Becciolini, A., Ditto, M. C., Del Medico, P., Farina, A., Visalli, E., Colella, A. Molica, Lumetti, F., Caccavale, R., Scolieri, P., Andracco, R., Girelli, F., Bravi, E., Colina, M., Volpe, A., Ianniello, A., Nucera, V., Franchina, V., Platé, I., and DI Donato, E.
- Published
- 2023
- Full Text
- View/download PDF
46. Effectiveness and safety of Everolimus-Exemestane (EVE-EXE) in unselected patients (pts) with HR + /HER2- Metastatic Breast Cancer (MBC): Our experience in clinical practice
- Author
-
Mafodda, A., primary, Giannicola, R., additional, Azzarello, D., additional, Del Medico, P., additional, Raffaele, M., additional, Giuffrè, C., additional, and Maisano, R., additional
- Published
- 2016
- Full Text
- View/download PDF
47. Characterization of tomato generations according to a three-way data analysis.
- Author
-
Del Medico, Ana Paula, Guadalupe Cabodevila, Victoria, Susana Vitelleschi, Maria, and Raúl Pratta, Guillermo
- Subjects
TOMATOES ,DATA analysis ,TOMATO varieties ,PLANT breeding ,FACTOR analysis ,FRUIT quality ,PLANT germplasm - Abstract
Availability of a three-way data analysis to characterize two consecutive tomato (Solanum lycopersicum) generations is necessary to continue a plant breeding program with less uncertainty. The aim of this work was to analyze tomato fruit quality from F2 and F3 populations by two three-way data analysis: multiple factorial analysis (MFA) and generalized procrustes analysis (GPA). These techniques have the same main objective, searching for a common structure, but they achieve it in different ways. This work evaluated 18 tomato genotypes, represented by individual plants in F2 and selfed families in F3. The same quantitative traits related to fruit quality were measured in both generations. The first two axes of the MFA represented 51.0% of the total variability. From the representation of the genotypes on these axes, traits differing from one generation to another were identified. The first two axes of the GPA represented 56.4% of the total variability. This analysis provided a table of analysis of variance (ANOVA), which corroborated the graphic and analytical interpretations of the MFA, a technique that provides the composition of the obtained axes. The comparison between the results obtained from these techniques indicated that both MFA and GPA allowed the detection of genotypes with discrepancies between the two generations. The MFA technique presented the advantage of studying graphically and analytically the nature and degree of phenotypic differences among genotypes in both generations, while the GPA complemented the analysis with an ANOVA, achieving the quantification of statistical significances for the discrepancies or similarities between them. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
- Author
-
Parisi, Simone, Andrea, Becciolini, Chiara, Ditto Maria, Lo Gullo, Alberto, Maddalena, Larosa, Palma, Scolieri, Olga, Addimanda, Massimo, Reta, Paroli, Marino, Rosalba, Caccavale, Elisa, Visalli, Rosario, Foti, Giorgio, Amato, Francesco, De Lucia, Ylenia, Dal Bosco, Roberta, Foti, Antonella, Farina, Francesco, Girelli, Simone, Bernardi, Dario, Camellino, Gerolamo, Bianchi, Matteo, Colina, Romina, Andracco, Natalia, Mansueto, Giulio, Ferrero, Patrizia, Del Medico, Aldo, Molica Colella, Veronica, Franchina, Francesco, Molica Colella, Federica, Lumetti, Gilda, Sandri, Carlo, Salvarani, Marta, Priora, Aurora, Ianniello, Valeria, Nucera, Daniele, Santilli, Gianluca, Lucchini, Adorni, Giuditta, Eleonora, Di Donato, Elena, Bravi, Ilaria, Platè, Eugenio, Arrigoni, Alessandra, Bezzi, Cristina, Focherini Maria, Fabio, Mascella, Vincenzo, Bruzzese, Viviana, Ravagnani, Alessia, Fiorenza, Guido, Rovera, Rosetta, Vitetta, Antonio, Marchetta, Alessandro, Volpe, Francesca, Ometto, Alarico, Ariani, and Enrico, Fusaro
- Abstract
The persistence in therapy of rheumatoid arthritis drugs and particularly bDMARD is a limiting factor for their long-term use. The randomized controlled trials (RCTs) may not reflect real-world contexts due to strict inclusion and exclusion criteria. Baricitinib, which targets both JAK1 and JAK2, has been used in Italy for several years. The aim of this multi-center study is to assess the real world persistence on therapy of baricitinib in RA patients and to identify predictive factors of baricitinib's survival rate.
- Published
- 2024
- Full Text
- View/download PDF
49. CAPILLAROSCOPIC SKIN ULCER RISK INDEX (CSURI) IN SYSTEMIC SCLEROSIS: RESULTS FROM AN ITALIAN MULTICENTER VALIDATION STUDY
- Author
-
Sebastiani, Marco, Manfredi, Andreina Teresa, Riato, L., Bocci, M., Iudici, M., Vukatana, G., Moscatelli, S., Principato, A., Mazzuca, S., Del Medico, P., De Angelis, R., Giuggioli, D., Colaci, Michele, and Ferri, Clodoveo
- Subjects
175 [CAPILLAROSCOPY ,SYSTEMIC SCLEROSIS ,DIGITAL ULCERS Ann Rheum Dis 2011,70(Suppl3)] ,DIGITAL ULCERS Ann Rheum Dis 2011 ,CAPILLAROSCOPY ,175 [70(Suppl3)] - Published
- 2011
50. Design and Off-Design Analysis of an ORC Coupled with a Micro-Gas Turbine.
- Author
-
Benato, Alberto, Stoppato, Anna, Mirandola, Alberto, and Del Medico, Marco
- Abstract
In the recent years, the possibility of recovering heat from gas turbine (GT) exhaust gases using Organic Rankine Cycles (ORC) have been largely explored. However, it is difficult to identify working fluids properly matching with micro-GT exhaust gases. For this reason, in the present work, the fluid selection and the plant layout optimization of an ORC which recovers the exhaust gases heat content of a 65 kW micro-gas turbine is presented. During the optimization process different plant configurations are considered: simple or regenerative and subcritical or transcritical. Exergy and economic analyses are also performed to estimate the exergy destruction rate and evaluate the economic feasibility of the optimized solutions. In order to find out the most suitable ORC unit and its behaviour, an off-design analysis is also performed using the commercial software Aspen Plus. Adopting a management strategy that maintains the turbine inlet temperature constant the best off-design performance is reached with Cyclopentane as working fluid. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.